% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Ehrenberg:194973,
      author       = {Ehrenberg, Alexander J and Kelberman, Michael A and Liu,
                      Kathy Y and Dahl, Martin J and Weinshenker, David and
                      Falgàs, Neus and Dutt, Shubir and Mather, Mara and Ludwig,
                      Mareike and Betts, Matthew J and Winer, Joseph R and Teipel,
                      Stefan and Weigand, Alexandra J and Eschenko, Oxana and
                      Hämmerer, Dorothea and Leiman Algranati, Marina and Counts,
                      Scott E and Shine, James M and Robertson, Ian H and Levey,
                      Allan I and Lancini, Elisa and Son, Gowoon and Schneider,
                      Chrisoph and Egroo, Maxime Van and Liguori, Claudio and
                      Wang, Qin and Vazey, Elena M and Rodriguez-Porcel, Federico
                      and Haag, Lena and Bondi, Mark W and Vanneste, Sven and
                      Freeze, Whitney M and Yi, Yeo-Jin and Maldinov, Mihovil and
                      Gatchel, Jennifer and Satpati, Abhijit and Babiloni, Claudio
                      and Kremen, William S and Howard, Robert and Jacobs, Heidi I
                      L and Grinberg, Lea T},
      title        = {{P}riorities for research on neuromodulatory subcortical
                      systems in {A}lzheimer's disease: {P}osition paper from the
                      {NSS} {PIA} of {ISTAART}.},
      journal      = {Alzheimer's and dementia},
      volume       = {19},
      number       = {5},
      issn         = {1552-5260},
      address      = {Hoboken, NJ},
      publisher    = {Wiley},
      reportid     = {DZNE-2023-00160},
      pages        = {2182-2196},
      year         = {2023},
      abstract     = {The neuromodulatory subcortical system (NSS) nuclei are
                      critical hubs for survival, hedonic tone, and homeostasis.
                      Tau-associated NSS degeneration occurs early in Alzheimer's
                      disease (AD) pathogenesis, long before the emergence of
                      pathognomonic memory dysfunction and cortical lesions.
                      Accumulating evidence supports the role of NSS dysfunction
                      and degeneration in the behavioral and neuropsychiatric
                      manifestations featured early in AD. Experimental studies
                      even suggest that AD-associated NSS degeneration drives
                      brain neuroinflammatory status and contributes to disease
                      progression, including the exacerbation of cortical lesions.
                      Given the important pathophysiologic and etiologic roles
                      that involve the NSS in early AD stages, there is an urgent
                      need to expand our understanding of the mechanisms
                      underlying NSS vulnerability and more precisely detail the
                      clinical progression of NSS changes in AD. Here, the NSS
                      Professional Interest Area of the International Society to
                      Advance Alzheimer's Research and Treatment highlights
                      knowledge gaps about NSS within AD and provides
                      recommendations for priorities specific to clinical
                      research, biomarker development, modeling, and intervention.
                      HIGHLIGHTS: Neuromodulatory nuclei degenerate in early
                      Alzheimer's disease pathological stages. Alzheimer's
                      pathophysiology is exacerbated by neuromodulatory nuclei
                      degeneration. Neuromodulatory nuclei degeneration drives
                      neuropsychiatric symptoms in dementia. Biomarkers of
                      neuromodulatory integrity would be value-creating for
                      dementia care. Neuromodulatory nuclei present strategic
                      prospects for disease-modifying therapies.},
      keywords     = {Humans / Alzheimer Disease: pathology / Brain: pathology /
                      Biomarkers / Disease Progression / Biomarkers (NLM
                      Chemicals)},
      cin          = {AG Düzel / AG Teipel},
      ddc          = {610},
      cid          = {I:(DE-2719)5000006 / I:(DE-2719)1510100},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      pmc          = {pmc:PMC10182252},
      pubmed       = {pmid:36642985},
      doi          = {10.1002/alz.12937},
      url          = {https://pub.dzne.de/record/194973},
}